–  NDA submission for etripamil in patients with PSVT currently on track for 3Q23 –  Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on Monday, May 22, 2023 –  Topline data from Phase 2 ReVeRA study evaluating etripamil in patients with AFib-RVR

Related Posts